Controlling the Cost of Drugs: the Canadian Experience

In 1969 Canada began programs at both the national and provincial levels to lower prescription drug prices. These programs may have contributed to a significant decline between 1970 and 1974 of 39 percent in the average price of 16 drugs selected for study. During this time, the average price for th...

Descripción completa

Detalles Bibliográficos
Autores principales: Fulda, Thomas K., Dickens, Paul F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: CENTERS for MEDICARE & MEDICAID SERVICES 1979
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4191072/
https://www.ncbi.nlm.nih.gov/pubmed/10309114
_version_ 1782338587841265664
author Fulda, Thomas K.
Dickens, Paul F.
author_facet Fulda, Thomas K.
Dickens, Paul F.
author_sort Fulda, Thomas K.
collection PubMed
description In 1969 Canada began programs at both the national and provincial levels to lower prescription drug prices. These programs may have contributed to a significant decline between 1970 and 1974 of 39 percent in the average price of 16 drugs selected for study. During this time, the average price for the same drugs in the United States declined only 1.4 percent. One major program, a change in the compulsory patent licensing, is described and analyzed. Other Canadian programs, designed to promote competition in the drug industry, and their effects are discussed.
format Online
Article
Text
id pubmed-4191072
institution National Center for Biotechnology Information
language English
publishDate 1979
publisher CENTERS for MEDICARE & MEDICAID SERVICES
record_format MEDLINE/PubMed
spelling pubmed-41910722014-11-04 Controlling the Cost of Drugs: the Canadian Experience Fulda, Thomas K. Dickens, Paul F. Health Care Financ Rev Original Research Article In 1969 Canada began programs at both the national and provincial levels to lower prescription drug prices. These programs may have contributed to a significant decline between 1970 and 1974 of 39 percent in the average price of 16 drugs selected for study. During this time, the average price for the same drugs in the United States declined only 1.4 percent. One major program, a change in the compulsory patent licensing, is described and analyzed. Other Canadian programs, designed to promote competition in the drug industry, and their effects are discussed. CENTERS for MEDICARE & MEDICAID SERVICES 1979 /pmc/articles/PMC4191072/ /pubmed/10309114 Text en
spellingShingle Original Research Article
Fulda, Thomas K.
Dickens, Paul F.
Controlling the Cost of Drugs: the Canadian Experience
title Controlling the Cost of Drugs: the Canadian Experience
title_full Controlling the Cost of Drugs: the Canadian Experience
title_fullStr Controlling the Cost of Drugs: the Canadian Experience
title_full_unstemmed Controlling the Cost of Drugs: the Canadian Experience
title_short Controlling the Cost of Drugs: the Canadian Experience
title_sort controlling the cost of drugs: the canadian experience
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4191072/
https://www.ncbi.nlm.nih.gov/pubmed/10309114
work_keys_str_mv AT fuldathomask controllingthecostofdrugsthecanadianexperience
AT dickenspaulf controllingthecostofdrugsthecanadianexperience

Ejemplares similares